Key Highlights

  • ARK Invest deployed approximately $240 million into OpenAI Group shares through three separate ETFs on March 31, 2026
  • OpenAI secured $122 billion in funding during the same trading session, achieving an $852 billion company valuation
  • ARK expanded holdings in CoreWeave and DoorDash through additional share purchases
  • ARK divested more than 600,000 shares of Strata Critical Medical while reducing Veracyte and Teradyne holdings
  • This transaction marks the first time retail ETF participants can gain indirect exposure to OpenAI through publicly available investment vehicles

Cathie Wood’s ARK Invest executed a significant portfolio maneuver on March 31, 2026, allocating approximately $240 million to OpenAI Group equity positions distributed among three exchange-traded funds.

The investment was distributed across the ARK Innovation ETF, the ARK Next Generation Internet ETF, and the ARK Blockchain and Fintech Innovation ETF. Each vehicle now maintains approximately 3% exposure to OpenAI Group PBC, Series C.

Prior to this transaction, OpenAI shares existed only within ARK’s closed-end Venture Fund portfolio. That particular fund initiated its OpenAI position in 2024, subsequently committing an additional $250 million during October of the same year.

ARK’s investment coincided with a landmark capital raise announcement from OpenAI. The artificial intelligence company finalized its most substantial funding round on the identical date, securing $122 billion and elevating its market valuation to $852 billion.

OpenAI indicated the capital would finance semiconductor acquisitions, data center expansion, and workforce growth. The organization simultaneously facilitated approximately $3 billion in direct share sales to individual participants through a private placement coordinated by three prominent financial institutions.

OpenAI CFO Sarah Friar expressed the company’s commitment to providing retail participants access to both its technological innovations and the corresponding economic benefits.

Implications for Everyday Investors

ARK’s decision to incorporate OpenAI shares within publicly traded ETFs creates a pathway for mainstream investors to obtain exposure to a private enterprise. This approach represents an uncommon opportunity, given that most individual investors lack access to pre-IPO equity positions.

The structure involves certain considerations. ETFs maintain continuous trading throughout market hours, while private company valuations lack real-time pricing mechanisms. Portfolio managers utilize estimated valuations for these assets and may need to liquidate other holdings to accommodate shareholder redemptions.

Cathie Wood addressed the investment decision, noting that agentic AI within the fintech landscape will generate exceptional opportunities.

Additional ARK Portfolio Activity on March 31

ARK’s trading activity extended beyond OpenAI. The firm acquired 26,515 shares of CoreWeave, a cloud infrastructure provider, representing roughly $2.05 million. CoreWeave experienced a 12% price increase during that session.

ARK additionally purchased 14,729 DoorDash shares valued at $2.21 million. This transaction followed a previous DoorDash acquisition from the prior trading day, expanding ARK’s exposure to the food delivery industry.

Regarding portfolio reductions, ARK liquidated 612,483 shares of Strata Critical Medical for $2.56 million. The healthcare logistics company specializes in urgent medical services for US healthcare facilities.

ARK further divested 6,204 Teradyne shares worth $1.84 million and eliminated 115,718 Veracyte shares across its ARKK and ARKG ETFs, totaling $3.52 million. ARK had been systematically decreasing its Veracyte allocation throughout the preceding week.

The OpenAI funding round concluded with an $852 billion valuation on March 31, 2026, coinciding precisely with ARK’s $240 million deployment across its three primary ETF products.